Difference between revisions of "Temozolomide (Temodar)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
Line 11: | Line 11: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
− | *[[ | + | *[[Anaplastic glioma]] |
− | |||
*[[CNS lymphoma]] | *[[CNS lymphoma]] | ||
+ | *[[Ewing's sarcoma]] | ||
+ | *[[Glioblastoma]] | ||
+ | *[[Low-grade glioma]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
*[[Myelodysplastic syndrome]] | *[[Myelodysplastic syndrome]] | ||
+ | *[[Neuroblastoma]] | ||
*[[Neuroendocrine tumors]] | *[[Neuroendocrine tumors]] | ||
+ | *[[Pancreatic NET]] | ||
*[[Soft tissue sarcoma]] | *[[Soft tissue sarcoma]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
Line 32: | Line 36: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
− | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Line 38: | Line 41: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
− | [[Category: | + | [[Category:Anaplastic glioma medications]] |
− | |||
[[Category:Central nervous system (CNS) lymphoma medications]] | [[Category:Central nervous system (CNS) lymphoma medications]] | ||
+ | [[Category:Ewing's sarcoma medications]] | ||
+ | [[Category:Glioblastoma medications]] | ||
+ | [[Category:Low-grade glioma medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Myelodysplastic syndrome medications]] | [[Category:Myelodysplastic syndrome medications]] | ||
+ | [[Category:Neuroblastoma medications]] | ||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
+ | [[Category:Pancreatic NET medications]] | ||
[[Category:Soft tissue sarcoma medications]] | [[Category:Soft tissue sarcoma medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
[[Category:Drugs FDA approved in 1999]] | [[Category:Drugs FDA approved in 1999]] |
Revision as of 16:06, 20 January 2018
Also known as Temcad and Temodal.
General information
Class/mechanism: Alkylator. Temozolomide is converted in vivo to the reactive compound 5-(3-methyltriazen-
1-yl)-imidazole-4-carboxamide (MTIC). MTIC causes alkylation of DNA at the O6 and N7 positions of guanine, leading to cell damage and cell death.[1][2][3]
Route: PO, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Anaplastic glioma
- CNS lymphoma
- Ewing's sarcoma
- Glioblastoma
- Low-grade glioma
- Melanoma
- Myelodysplastic syndrome
- Neuroblastoma
- Neuroendocrine tumors
- Pancreatic NET
- Soft tissue sarcoma
- Small cell lung cancer
Patient drug information
- Temozolomide (Temodar) patient drug information from manufacturer[4]
- Temozolomide (Temodar) patient drug information (Chemocare)[5]
- Temozolomide (Temodar) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 8/11/1999: Initial FDA approval
References
- ↑ 1.0 1.1 Temozolomide (Temodar) package insert
- ↑ Temozolomide (Temodar) package insert (locally hosted backup)
- ↑ Temodar manufacturer's website
- ↑ Temozolomide (Temodar) patient drug information from manufacturer
- ↑ Temozolomide (Temodar) patient drug information (Chemocare)
- ↑ Temozolomide (Temodar) patient drug information (UpToDate)
- Drug index
- Intravenous medications
- Oral medications
- Alkylating agents
- Acute myeloid leukemia medications
- Anaplastic glioma medications
- Central nervous system (CNS) lymphoma medications
- Ewing's sarcoma medications
- Glioblastoma medications
- Low-grade glioma medications
- Melanoma medications
- Myelodysplastic syndrome medications
- Neuroblastoma medications
- Neuroendocrine tumor medications
- Pancreatic NET medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Drugs FDA approved in 1999